Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Aravax has raised $22.2M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Aravax's investors include Brandon Capital, Uniseed, Novartis Venture Fund, Breakthrough Victoria, Tenmile.
Aravax is headquartered in Melbourne, Australia.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Aravax is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aravax — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/aravax. Accessed August 14, 2026.
VCBacked. (2024). Aravax — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/aravax
{{cite web |title=Aravax — Funding & Investors |url=https://www.vcbacked.co/company/aravax |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated